EPI-IBD: A multicentre IBD Inception Cohort Study
Research type
Research Study
Full title
EPI-IBD: A Multicentre inflammatory bowel disease longitudinal inception cohort study evaluating disease progression in IBD.
IRAS ID
242993
Contact name
Shaji Sebastian
Contact email
Sponsor organisation
Hull University Teaching Hospitals NHS Trust
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Crohn's disease (CD) and Ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) of unknown aetiology affecting over 3 million people in Europe. It mainly affects young adults, causing significant morbidity and impacting quality of life
Despite significant advances in therapy,the impact of these on the natural history of disease, measurable outcomes such as surgery rates in IBD is unclear and IBD remains a disabling disease that profoundly impacts patients’ lives.The challenge remains to select the patients who will benefit most from early intensive therapy, while sparing those who will derive minimal benefit from such treatment. Therefore, the ability to predict progression of disease, as well as identify ‘red flags’ that could alert the clinician to an impending flare or relapse, will be extremely valuable.
The goal of this prospective European inception cohort study is to promote a greater understanding of the long-term evolution of , better elucidate the impact of different therapeutic strategies, and develop accurate predictors of bowel disease damage and disability.We will explore predictors of disease progression and responses to medical therapy in addition to prognostic implications of the degree of organ damage. Furthermore the impact of quality of care in disease outcomes will be explored.The relationship between disease course, diet and microbiome will also be studied in CD for deeper understanding of disease progression.The particpants will be recruited from participating hospitals at or soon after diagnosis. Potential patients will be identified by their Consultant Gastroenterologist based on their new IBD diagnosis. We will collect data on clinical presentation, diagnostic parameters, disease specific severity indices and QoL measures. The participants will be the followed up in their normal care settings and observational data will be collected bi-annually for 5 years. The participants will be requested to fill QoL questionnaires at inclusion and annually.
REC name
Yorkshire & The Humber - Bradford Leeds Research Ethics Committee
REC reference
19/YH/0019
Date of REC Opinion
23 Jan 2019
REC opinion
Favourable Opinion